CLINICAL TRIALS PROFILE FOR FELODIPINE

All Clinical Trials for FELODIPINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00841880 ↗	China Medical University Hospital (CMUH) Triapin Listing	Completed	Sanofi	Phase 4	2009-01-01	The objective of this study is to compare the reduction in office seated systolic blood pressure (BP) following a 8 weeks regimen of ramipril 5mg plus felodipine 5mg versus ramipril 10mg. To compare the response rate (defined as office systolic blood pressure (SBP) / Diastolic blood pressure (DBP) reduce more than 10mmHg from baseline), and BP controlled rate (defined as SBP<140mmHg and/or DBP<90mmHg) and as SBP < 130 mmHg and /or DBP < 80 mmHg in diabetes,chronic kidney disease, known Coronary Arterial Disease (CAD) or CAD equivalent, or 10-year Framingham risk score > 10%. To ascertain the safety and tolerability of ramipril/felodipine versus ramipril in Taiwanese population. To compare compliance with fixed dose combination of ramipril/felodipine versus ramipril treatment.
NCT00905333 ↗	Evaluation of the Pharmacokinetic Interaction Between Candesartan and Felodipine After Ingestion of a Specific Meal	Completed	Clínica São Lucas, Hospital Sírio Libanês de Itatiba S/C	Phase 1	2008-10-01	The purpose of this study is to evaluate the pharmacokinetic interaction of test formulations of candesartan and felodipine in a combination package comparing with the fasting intake of commercial formulations of both Atacand ® and Splendil®
NCT00742066 ↗	Role of AT1-receptor Blockers in Insulin-induced Vasodilation.	Unknown status	Maastricht University Medical Center	N/A	2008-03-01	In this study we hypothesize that blocking the angiotensin II AT1-receptor improves the insulin-induced microvascular dilatation. Objectives: 1. Does blockade of the angiotensin II AT1-receptor improve the insulin-induced microvascular effects in hypertensive patients. 2. Does blockade of the angiotensin II AT1-receptor impair the insulin-induced microvascular effects in normotensive control subjects?
NCT00507845 ↗	Use of Ramipril and Felodipine Combination Therapy in Hypertension: An Effectiveness Study With Local Patients in Argentina	Completed	Sanofi	Phase 4	2007-06-01	Primary: - To assess effectiveness of Ramipril-Felodipine in hypertensive Argentinean patients Secondary: - To assess tolerability of Ramipril-Felodipine in hypertensive Argentinean patients.
NCT00392262 ↗	A Study to Evaluate the Combination of Valsartan + Amlodipine in Hypertensive Patients	Completed	Novartis	Phase 3	2006-08-01	The purpose of this study is to evaluate the efficacy of valsartan plus amlodipine in hypertensive patients not responding to treatment with amlodipine or felodipine alone.
NCT00348686 ↗	Candesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP)	Completed	AstraZeneca	Phase 4	2006-06-01	The purpose of this study is to investigate effect of candesartan based therapy on percent change of B type natriuretic peptides(BNP) level in the subjects with hypertension and left ventricular hypertrophy.
NCT00367939 ↗	Efficacy and Safety of the Combination of Valsartan Plus Amlodipine in Hypertensive Patients Not Adequately Responding to the Combination Therapy With Ramipril Plus Felodipine	Completed	Novartis	Phase 3	2005-12-01	The purpose of this study is to evaluate the efficacy of valsartan plus amlodipine in hypertensive patients not responding to treatment with ACE inhibitor plus calcium channel blocker

Clinical Trial Conditions for FELODIPINE

Condition Name

Condition Name for FELODIPINE
Intervention	Trials
Hypertension	13
Healthy	5
Insulin Resistance	1
Left Ventricular Hypertrophy	1

Condition MeSH

Condition MeSH for FELODIPINE
Intervention	Trials
Hypertension	13
Malnutrition	2
Insulin Resistance	1
Hypertrophy, Left Ventricular	1

Clinical Trial Locations for FELODIPINE

Trials by Country

+

−

Trials by Country for FELODIPINE
Location	Trials
China	4
Brazil	2
India	2
Germany	2
Argentina	1

Clinical Trial Progress for FELODIPINE

Clinical Trial Phase

Clinical Trial Phase for FELODIPINE
Clinical Trial Phase	Trials
Phase 4	8
Phase 3	2
Phase 1	5

Clinical Trial Status

Clinical Trial Status for FELODIPINE
Clinical Trial Phase	Trials
Completed	15
Recruiting	2
Unknown status	2

Clinical Trial Sponsors for FELODIPINE

Sponsor Name

Sponsor Name for FELODIPINE
Sponsor	Trials
AstraZeneca	3
Torrent Pharmaceuticals Limited	2
Ranbaxy Laboratories Limited	2

Sponsor Type

Sponsor Type for FELODIPINE
Sponsor	Trials
Other	15
Industry	15

Felodipine: Clinical Trials, Market Analysis, and Projections

Introduction to Felodipine

Felodipine is a calcium channel blocker primarily used to manage hypertension and angina pectoris. It works by relaxing the blood vessels, allowing blood to flow more easily and reducing blood pressure. Here, we will delve into the latest clinical trials, market analysis, and future projections for felodipine.

Clinical Trials Update

Felodipine in Huntington’s Disease

A recent clinical trial has explored the use of felodipine in a novel context: early-stage Huntington’s disease (HD). This Phase II trial aimed to assess the safety and tolerability of different doses of felodipine in patients with genetically and clinically confirmed early-stage HD. The trial involved 18 participants aged 35-70 years, who were administered felodipine in varying doses (2.5 mg to 20 mg once daily) over a 58-week treatment period, followed by a 4-week washout period[1].

The primary outcome measure was the number of adverse events attributable to felodipine. While the trial has been completed, the results are not yet publicly available. However, the study's design suggests a promising avenue for investigating the potential of felodipine in upregulating autophagy, a process that could help clear the abnormal protein associated with HD.

Safety Profile in Hypertension

Historical clinical trials have consistently shown that felodipine is safe and effective in managing hypertension. A comprehensive safety analysis of clinical trials with felodipine indicated that it does not increase mortality or the incidence of major cardiovascular events and has a favorable safety profile[3].

Market Analysis

Market Size and Growth

The felodipine extended-release tablets market is driven by several key factors, including the growing prevalence of hypertension among the aging population, expanding pharmaceutical investments, and rising healthcare expenditures. The market is expected to grow significantly from 2025 to 2030, with opportunities arising from emerging markets and the increasing adoption of extended-release medications[2].

Market Dynamics

• Market Drivers: The growing prevalence of hypertension, expanding pharmaceutical investments, and rising healthcare expenditures are key drivers for the felodipine market.
• Market Restraints: Competitive pressures from alternative medications, regulatory challenges, and consumer resistance to switching from brand drugs are significant restraints.
• Market Opportunities: Enhancing online presence, capitalizing on the rising prevalence of hypertension, and targeting specialized hypertensive conditions offer potential growth opportunities[2].

Distribution Channels and End-Users

Felodipine extended-release tablets are distributed through various channels, including clinics, pharmacies, and wholesale distributors. The primary application scope includes cardiovascular health management within healthcare institutions, retail pharmacies, and specialized clinics. The market is influenced by factors such as patient age group, application, end-user, formulation type, and therapeutic category[2].

Competitive Landscape

The felodipine market is competitive, with several key players including AstraZeneca plc, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., and others. These companies are involved in strategic alliances, research and development, and leveraging digital health technologies to maintain their market position[2].

Projections and Future Outlook

Market Penetration and Development

The felodipine market is expected to see increased penetration in emerging markets, driven by rising healthcare expenditures and better healthcare infrastructure. The report suggests that companies should focus on expanding their presence in these markets and diversifying their product offerings to capture new opportunities[2].

Product Development and Innovation

Future growth in the felodipine market will be driven by product innovation, including advancements in pharmaceutical formulations and the integration of digital health technologies. Companies are expected to invest in research and development to enhance the therapeutic outcomes of felodipine and to address unmet needs in cardiovascular health management[2].

Regulatory and Competitive Challenges

Navigating complex regulatory landscapes and overcoming competitive pressures will remain crucial for the success of felodipine in the market. Companies must be prepared to manage supply chain disruptions and consumer resistance to switching from brand drugs, while also ensuring timely regulatory approvals for market entry[2].

Key Takeaways

• Clinical Trials: Felodipine is being explored for its potential in treating early-stage Huntington’s disease, in addition to its established use in hypertension and angina pectoris.
• Market Growth: The felodipine extended-release tablets market is expected to grow significantly from 2025 to 2030, driven by the growing prevalence of hypertension and rising healthcare expenditures.
• Market Dynamics: The market is influenced by various factors, including competitive pressures, regulatory challenges, and opportunities for expansion in emerging markets.
• Competitive Landscape: The market is competitive, with several key players involved in strategic alliances and research and development to maintain their market position.

FAQs

What is the primary use of felodipine?

Felodipine is primarily used to manage hypertension and angina pectoris by relaxing the blood vessels and reducing blood pressure.

Is felodipine being explored for other medical conditions?

Yes, felodipine is being explored for its potential in treating early-stage Huntington’s disease, in addition to its established use in cardiovascular conditions.

What are the key drivers for the felodipine market?

The key drivers include the growing prevalence of hypertension, expanding pharmaceutical investments, and rising healthcare expenditures.

Who are the major players in the felodipine market?

Major players include AstraZeneca plc, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., and others.

What are the potential challenges for the felodipine market?

Challenges include competitive pressures from alternative medications, regulatory challenges, and consumer resistance to switching from brand drugs.

Sources

1. A trial to look at how different doses of felodipine are tolerated in people with early-stage Huntington’s disease. Retrieved from https://www.isrctn.com/pdf/56240656
2. Felodipine Extended-Release Tablets Market Size 2025-2030. Retrieved from https://www.360iresearch.com/library/intelligence/felodipine-extended-release-tablets
3. Overview of the safety of felodipine based on clinical trials. Retrieved from https://pubmed.ncbi.nlm.nih.gov/9104926/
4. Treatment of stable angina pectoris: focus on the role of calcium antagonists and ACE inhibitors. Retrieved from https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-15/Treatment-of-stable-angina-pectoris-focus-on-the-role-of-calcium-antagonists-and-ACE-inhibitors
5. Felodipine Sustained-Release Tablet | Market Research Reports® Inc. Retrieved from https://www.marketresearchreports.com/mrrpb5/felodipine-sustained-release-tablet-global-market-share-and-ranking-overall-sales-and-demand